1. Home
  2. ICPJL
  3. Targeting the integrin alpha4beta7 with probiotics and nutraceuticals a working hypothesis
Submit manuscript...
eISSN: 2471-0016

International Clinical Pathology Journal

Opinion Volume 3 Issue 1

Targeting the integrin α4β7 with probiotics and nutraceuticals: a working hypothesis

Ilaria Peluso

1Centre for Food and Nutrition, Council for Agricultural Research and Economics, Italy
1Centre for Food and Nutrition, Council for Agricultural Research and Economics, Italy

Correspondence: Ilaria Peluso, Centre for Food and Nutrition, Council for Agricultural Research and Economics, Via Ardeatina 546, Rome, Italy, Tel 3965 1494 560, Fax 3965 1494 550

Received: January 01, 1971 | Published: November 4, 2016

Citation: Peluso I. Targeting the integrin ?4?7 with probiotics and nutraceuticals: a working hypothesis. Int Clin Pathol J. 2016;3(1):183–185. DOI: 10.15406/icpjl.2016.03.00068

Download PDF

Abstract

α4β7 integrin is critical in lymphocyte homing to the gut, a clinical relevant marker and a therapeutic target in inflammatory bowel disease (IBD). Deregulated β7-mediated T lymphocytes homing was observed also in the extra-intestinal manifestations of IBD and in subjects with the irritable bowel syndrome (IBS). Nutritional interventions and/or functional foods (containing prebiotics, probiotics and/or nutraceuticals), rather than drug treatments, should be recommended in IBS. Despite dysbiosis is a common feature of both IBD and IBS, the modulation of gut microbiota and gut functional symptoms by dietary regimes, prebiotics, probiotics, symbiotics, as well as by herbal medicinal products and foods containing bioactive phytochemicals, requires future well-designed clinical trials to establish their safety and efficacy. Results from in vitro and animal models suggest a role of α4β7 integrin also in high-fat diet (HFD)-induced insulin resistance (IR) and atherosclerosis, as well as the potential modulation of gut homing by dietary phytochemicals and probiotics. Despite there was no significant difference in cholesterol levels between HFD fed ApoE-/- and β7-/-ApoE-/-mice, the latter had a reduced the size of atherosclerotic lesions. Overall human and experimental data suggest that α4β7 integrin could be a target of functional foods and a useful marker in human studies, being sensitive to the complex interaction between genetic factors, microbiota and dietary habit.

Keywords: α4β7 integrin, apolipoprotein e, dietary phytochemicals, functional foods, gut-associated lymphoid tissue, gut-homing, nutraceuticals, human studies, polyphenols, prebiotics, probiotics

Abbreviations

Apo E, apolipoprotein E; DC, dendritic cell; FODMAPs, fermentable oligosaccharides, disaccharides, monosaccharide and polyols; GALT, gut-associated lymphoid tissue; HFD, high-fat diet; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; IR, insulin resistance; LcS, lactobacillus casei shirota; MAdCAM-1, mucosal address in cell adhesion molucule-1; PUFA, polyunsaturated fatty acids; UC, ulcerative colitis

Introduction

The gut-homing molecule α4β7 integrin is a clinical relevant marker in celiac disease1cow's milk allergy,2 HIV-1 infection,3,4 mucosal responses to bacterial infection,5 post- hematopoietic stem cell transplantation diabetes mellitus6,7 and graft-versus-host disease.8–10 Aberrant homing of mucosal T cells plays a role also in the extra-intestinal manifestations of inflammatory bowel disease (IBD).11 In this context, α4β7 integrin is an emerging therapeutic target IBD.12–14 Deregulated β7-mediated T lymphocytes homing was observed also in patients with gastrointestinal disorders, such as irritable bowel syndrome (IBS)15–17 and functional dyspepsia.18 Although these conditions impair patients' quality of life, nutritional interventions and/or functional foods (containing prebiotics, probiotics and/or nutraceuticals) rather than drug treatments should be recommended.

Prebiotics, probiotics and nutraceuticals

Dysbiosis is a common feature of both IBD and IBS,19 but the therapeutic modulation of gut microbiota and symptoms by dietary regimes, prebiotics, probiotics, symbiotic, as well as by herbal medicinal products and foods containing bioactive phytochemicals, requires future well-designed clinical trials to establish their safety and efficacy.20–26 Whereas the role of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) in eliciting IBS requires further investigations,27 a diet low FODMAPs is increasingly recommended for patients with IBD.28 FODMAPs are found in many vegetables and fruits,29 rich food-sources of polyphenols. Despite the suggested prebiotics, anti-inflammatory, anti-oxidant and immuno-modulatory activities of polyphenols, potential adverse effects due to their interaction with the phase I, II and III metabolizing/transport system must be take into account.30 Also food-drug interactions with statins are a commonly overlooked aspect.31 In this context, the cross-talk between the Gut-Associated Lymphoid Tissue (GALT) and microbiota has a role also in metabolic syndrome.32 Both in vitro and in vivo studies suggest that many interactions could occur among probiotics, prebiotics, omega 3 polyunsaturated fatty acids (w-3 PUFA) and polyphenols from dietary or non-dietary sources in the GALT.33 Prebiotics, w-3 PUFA and polyphenols affect the colonic microflora.33 The latter converts polyphenols into metabolites with different activities that could directly interact with immune cells in the GALT.33 Despite the evidence of the mutual cooperation among prebiotics, w-3 PUFA and polyphenols in the prevention of metabolic syndrome, suggesting that Mediterranean diet is a natural multiple supplement.33 studies in mice and human subjects indicate that the Apolipoprotein E (ApoE) 3 genotype, which has high frequency in the Mediterranean area, may significantly benefit from dietary flavonoids and w-3 PUFA.34 On the contrary, the apoE4 genotype, the most important genetic risk factors for age-dependent chronic diseases showing high frequency in Northern Europe, is associated with higher circulating vitamin D levels.34

The role of vitamin D and A in the induction of homing properties in T cells is well known.35 Results from animal models suggest a primary role of α4β7 in high-fat diet (HFD)-induced insulin resistance (IR)36 and atherosclerosis.37 HFD-induced IR was lower in β7 integrin-deficient mice (β7-/-) versus control wild-type C57BL/6mice.36 α4β7 and its ligand mucosal addressin cell adhesion molucule-1 (MAdCAM-1) were up-regulated in HFD-induced atherosclerotic lesions in the ApoE-/-mouse model of atherosclerosis.37 The increase in plaque area in HFD fed ApoE-/-aortas occurs in parallel with an increase in peripheral blood lymphocyte α4β7 integrin expression.37 The genetic deletion of β7 integrin reduced the size of the HFD-induced atherosclerotic lesions in ApoE-/- mice, despite there was no significant difference in cholesterol levels between HFD fed ApoE-/-and β7-/-ApoE-/-mice.37 Also intestinal bacteria influence the development of atherosclerotic in ApoE-/- mice.38

A high cholesterol diet, but not a low cholesterol diet, induced atherosclerotic aortic plaques ApoE-/-mice.38 However, a diet low in cholesterol induced atherosclerotic plaques in ApoE-/-mice in germ-free conditions.38 Differential immuno-modulatory effects of probiotic strain Lactobacillus casei Shirota (LcS) on human dendritic cell (DC) from healthy controls and active in ulcerative colitis (UC) patients have been reported.39 LcS treated DC from healthy subjects induced β7 on T cells and enhanced DC ability to induce transforming growth factor-β production by T cells, but had no effects on UC-DC.39

On the other hand, in vitro experiments indicate that the unsaponifiable fraction of extra virgin olive oil is able to reduce the expression of integrin α4β7 on T lymphocytes from peripheral blood of patients with IBD,40 suggesting a potential modulation of gut homing by dietary phytochemicals.

Conclusion

Overall human and experimental data suggest that α4β7 integrin could be a target of functional foods and a useful marker in human studies, being sensitive to the complex interaction between genetic factors, microbiota and dietary habits.

Acknowledgements

Author was supported by the grant of the Italian Ministry of Agricultural, Nutritional Policies and Forestry (MiPAAF - MEDITO).

Conflict of interest

There is no conflict of interests regarding the publication of this paper.

References

  1. Lammi A, Arikoski P, Vaarala O, et al. Increased peripheral blood CD4+ T cell responses to deamidated but not to native gliadin in children with coeliac disease. Clin Exp Immunol. 2012;168(2):207–214.
  2. Eigenmann PA, Tropia L, Hauser C. The mucosal adhesion receptor alpha4beta7 integrin is selectively increased in lymphocytes stimulated with beta-lactoglobulin in children allergic to cow's milk. J Allergy Clin Immunol. 1999;103(5 Pt 1):931–936.
  3. Lu X, Li Z, Li Q, et al. Preferential loss of gut-homing α4β7 CD4+ T cells and their circulating functional subsets in acute HIV-1 infection. Cell Mol Immunol. 2015;10.1038/cmi.2015.60.
  4. Chisenga CC, Filteau S, Siame J, et al. T-Cell Subsets Predict Mortality in Malnourished Zambian Adults Initiating Antiretroviral Therapy. PLoS One. 2015;10(6):e0129928.
  5. Bhuiyan TR, Hoq MR, Nishat NS, et al. Enumeration of gut-homing β7-positive, pathogen-specific antibody-secreting cells in whole blood from enterotoxigenic escherichia coli- and vibrio cholerae-infected patients, determined using an enzyme-linked immunosorbent spot assay technique. Clin Vaccine Immunol. 2015;23(1):27–36.
  6. Engelhardt BG, Jagasia SM, Crowe JE Jr, et al. Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity. Blood. 2012;119(10):2417–2421.
  7. Engelhardt BG, Jagasia M, Savani BN, et al. Regulatory T cell expression of CLA or α(4)β(7) and skin or gut acute GVHD outcomes. Bone Marrow Transplant. 2011;46(3):436–442.
  8. Engelhardt BG, Sengsayadeth SM, Jagasia M, et al. Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival. Exp Hematol. 2012;40(12):974–982.
  9. Engelhardt BG, Jagasia M, Savani BN, et al. Regulatory T cell expression of CLA or α(4)β(7) and skin or gutacute GVHD outcomes. Bone Marrow Transplant. 2011;46(3):436–442.
  10. Chen YB, McDonough S, Chen H, et al. Expression of α4β7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD. Bone Marrow Transplant. 2013;48(4):598–603.
  11. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006;6(3):244–251.
  12. Manuc TE, Manuc MM, Diculescu MM. Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets. Clin Exp Gastroenterol. 2016;9:59–70.
  13. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711–721.
  14. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
  15. Ohman L, Isaksson S, Lundgren A, et al. As controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005;3(10):980–986.
  16. Rodríguez-Fandiño O, Hernández-Ruíz J, López-Vidal Y, et al. Intestinal recruiting and activation profiles in peripheral blood mononuclear cells in response to pathogen-associated molecular patterns stimulation in patients with IBS. Neurogastroenterol Motil. 2013;25(11):872–e699.
  17. Matricon J, Meleine M, Gelot A, et al. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther. 2012;36(11-12):1009–1031.
  18. Liebregts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol. 2011;106(6):1089–1098.
  19. Spiller R, Major G. IBS and IBD - separate entities or on a spectrum? Nat Rev Gastroenterol Hepatol. 2016;13(10):613–621.
  20. Currò D, Ianiro G, Pecere S, et al. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol. 2016;10.1111/bph.13632.
  21. Qiao YQ, Cai CW, Ran ZH. Therapeutic modulation of the gut microbiota in IBD - more questions to be answered. J Dig Dis. 2016;10.1111/1751-2980.
  22. Farzaei MH, Bahramsoltani R, Abdolghaffari AH, et al. A mechanistic review on plant-derived natural compounds as dietary supplements for prevention of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2016;10(6):745–758.
  23. Schaubeck M, Haller D. Reciprocal interaction of diet and microbiome in inflammatory bowel diseases. Curr Opin Gastroenterol. 2015;31(6):464–470.
  24. Matijašić M, Meštrović T, Perić M, et al. Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. Int J Mol Sci. 2016;17(4).
  25. Parian A, Limketkai BN. Dietary supplement therapies for inflammatory bowel disease: Crohn's disease and ulcerative colitis. Curr Pharm Des. 2016;22(2):180–188.
  26. Martinez RC, Bedani R, Saad SM. Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: an update for current perspectives and future challenges. Br J Nutr. 2015;114(12):1993–2015.
  27. De Giorgio R, Volta U, Gibson PR. Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction? Gut. 2016;65(1):169–178.
  28. Durchschein F, Petritsch W, Hammer H. Diet therapy for inflammatory bowel diseases: The established and the new. World J Gastroenterol. 2016;22(7):2179–2194.
  29. Muir JG, Rose R, Rosella O, et al. Measurement of short-chain carbohydrates in common Australian vegetables and fruits by high-performance liquid chromatography (HPLC). J Agric Food Chem. 2009;57(2):554–565.
  30. Kaulmann A, Bohn T. Bioactivity of polyphenols: preventive and adjuvant strategies toward reducing inflammatory bowel diseases-promises, perspectives, and pitfalls. Oxid Med Cell Longev. 2016.
  31. Peluso I, Palmery M, Serafini M. Association of flavonoid-rich foods and statins in the management of hypercholesterolemia: a dangerous or helpful combination? Curr Drug Metab. 2015;16(9):833-846.
  32. Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65(2):330–339.
  33. Peluso I, Romanelli L, Palmery M. Interactions between prebiotics, probiotics, polyunsaturated fatty acids and polyphenols: diet or supplementation for metabolic syndrome prevention? Int J Food Sci Nutr. 2014;65(3):259–267.
  34. Egert, Rimbach G, Huebbe P. ApoE genotype: from geographic distribution to function and responsiveness to dietary factors. Proc Nutr Soc. 2012;71(3):410–424.
  35. Sigmundsdottir H, Butcher EC. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol. 2008;9(9):981–987.
  36. Luck H, Tsai S, Chung J, et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab. 2015;21(4):527–542.
  37. Zhi K, Li M, Zhang X, et al. α4β7 Integrin (LPAM-1) is upregulated at atherosclerotic lesions and is involved in atherosclerosis progression. Cell Physiol Biochem. 2014;33(6):1876–1887.
  38. Stepankova R, Tonar Z, Bartova J, et al. Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet. J Atheroscler Thromb. 2010;17(8):796–804.
  39. Mann ER, You J, Horneffer-van der Sluis V, et al. Dysregulated circulating dendritic cell function in ulcerative colitis is partially restored by probiotic strain Lactobacillus casei Shirota. Mediators Inflamm. 2013;2013:573576..
  40. Cárdeno A, Magnusson MK, Strid H, et al. The unsaponifiable fraction of extra virgin olive oil promotes apoptosis and attenuates activation and homing properties of T cells from patients with inflammatory bowel disease. Food Chem. 2014;161:353–360.
Creative Commons Attribution License

©2016 Peluso. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.

Citations

Editor's Voice

Journal Menu

Useful Links